Aducanumab therapy to treat Alzheimer's disease: A narrative review
Background. Aducanumab, a new monoclonal antibody that targets β-amyloid aggregates, has been granted conditional approval by the U.S. FDA for treatment of mild Alzheimer's disease (AD). The approval of this drug without a confirmed significant clinical impact has resulted in several debates. O...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Published: |
Hindawi Limited
2022
|
| Subjects: | |
| Online Access: | http://eprints.um.edu.my/43312/ https://www.scopus.com/inward/record.uri?eid=2-s2.0-85127019773&doi=10.1155%2f2022%2f9343514&partnerID=40&md5=801b7d2ee5bb21c92387c5ef2b9dbdb4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|